TNF and inflammatory bowel disease: Wong et al. found a serological conversion rate of 100% in 26 IBD patients, who completed two doses of vaccination with BNT162b2 or mRNA-1273 (TNF antagonist (n = 8), vedolizumab (n = 12), ustekinumab (n = 2), no medication (n = 4)).